Attribuer, s’approprier et construire l’espace urbain colonial by Sofie Boonen

Get full text

Une ville construite par des « gens d’ailleurs ». Développements urbains à Elisabethville, Congo belge (actuellement Lubumbashi, RDC) by Sofie Boonen

Get full text

Clinicians need to treat underlying osteoporosis. by Wahl, D, Cooper, C, Boonen, S

Recidiverend vallen, osteoporose en sarcopenie, drie belangrijke problemen, een geïntegreerde benadering by E. Dejaeger, S. Boonen, J. Coussement, K. Milisen

Get full text

Evaluatie van de interne geriatrische consultfunctie in Belgische Ziekenhuizen by Mieke Deschodt, Johan Flamaing, Steven Boonen, Koen Milisen

Get full text

Testosterone and the Male Skeleton: A Dual Mode of Action by Mieke Sinnesael, Steven Boonen, Frank Claessens, Evelien Gielen, Dirk Vanderschueren

Get full text

Machine Learning-Based Analysis Reveals Triterpene Saponins and Their Aglycones in <i>Cimicifuga racemosa</i> as Critical Mediators of AMPK Activation by Jürgen Drewe, Verena Schöning, Ombeline Danton, Alexander Schenk, Georg Boonen

Get full text

Effectiveness and cost-effectiveness of combined asynchronous telemonitoring and patient-initiated care for spondyloarthritis: protocol for a pragmatic multicentre randomised contr... by Astrid van Tubergen, Annelies Boonen, Harald E Vonkeman, Kasper Hermans

Get full text

Not all patients are average: The importance of epidemiological data in pharmacoeconomic modeling by van Staa, T, Boonen, A, Geusens, P, Cooper, C, Leufkens, H

The use of individual risks rather than population averages in cost-effectiveness modeling by Van Staa, T, Geusens, P, Boonen, A, Leufkens, H, Cooper, C

The use of individual risks rather than PopulationAverages in cost-effectiveness modeling by van Staa, T, Geusens, P, Boonen, A, Cooper, C, Leufkens, H

Not all patients are average: The importance of recognising patient heterogeneity by Van Staa, T, Geusens, P, Boonen, A, Leufkens, H, Cooper, C

Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis by Sara Peeters, Kurt De Vlam, Hugo Boonen, Canan Güvenç, Tom Hillary

Get full text

Getting prepared for the silver wave: challenges in conducting rheumatic and musculoskeletal disease research in older adults by Annelies Boonen, Marloes van Onna, Fabienne Magdelijns, Saskia Truijen, Shennah Austen

Get full text

Laattijdige neuropsychologisch syndroom na COintoxicatie bij een bejaarde vrouw by l Vander Weyden, r Voigt, s Boonen, k Fagard, e DeJaeger

Get full text

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. by van Staa, T, Geusens, P, Zhang, B, Leufkens, H, Boonen, A, Cooper, C

The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. by van Staa, T, Kanis, J, Geusens, P, Boonen, A, Leufkens, H, Cooper, C

A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis by Taylor, P, van der Heijde, D, Landewé, R, McCue, S, Cheng, S, Boonen, A

Fragment ion intensity prediction improves the identification rate of non-tryptic peptides in timsTOF by Charlotte Adams, Wassim Gabriel, Kris Laukens, Mario Picciani, Mathias Wilhelm, Wout Bittremieux, Kurt Boonen

Get full text

Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. by Boonen, S, Bischoff-Ferrari, H, Cooper, C, Lips, P, Ljunggren, O, Meunier, P, Reginster, J